In 303 adults with active SLE without proliferative or membranous nephritis on standard therapy, obinutuzumab gave more SRI-4 responses at week 52 than placebo (76.7% vs 53.5%; P<0.001). Serious adverse events: 15.9% vs 11.9%.
RCTn = 303
Furie et al. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus